Likes Subject
YES, great news! Glad I stuck around Jwit56 02/26/20 3:37 AM
Looks like the merger has been approved. dwh 05/06/16 8:18 PM
SVACD, SciVac Nasdaq Listing news! UHD 05/06/16 1:59 AM
SVACF one for 40 reverse split effective May 2,2016: Renee 05/05/16 9:18 AM
Announced the R/S today. Between that and Mako my Day 04/29/16 8:41 AM
tic - toc ... one more week ... dwh 04/28/16 11:17 AM
SVACF, VBI meeting set for May 5, 2016! UHD 04/08/16 1:19 PM
I believe it will be just like COCP, UHD 03/28/16 1:35 PM
Has anyone contacted the company to find out serious38 03/28/16 1:15 PM
"Pursuant to the merger agreement, SciVac and VBI UHD 03/25/16 6:07 PM
Agree. The price broke the 50-day MA so thought013 03/17/16 5:32 PM
SVACF going to run soon imo. Merger to UHD 03/17/16 11:17 AM
My thoughts exactly and I have been averaging thought013 02/19/16 5:41 PM
Think that recall news and no news has Mako my Day 02/18/16 8:29 AM
SVACF appears to be a lost cause until UHD 12/10/15 4:30 PM
I never saw it hit below .12 today, serious38 12/10/15 4:29 PM
under .10 soon? UHD 12/07/15 10:42 AM
In today. Barry Honig 13G filed. Frost cling RealGenius 12/02/15 1:34 PM
Only what the Co has told us. UHD 11/12/15 1:49 AM
You've gotten your wish. Has any date been serious38 11/11/15 4:08 PM
Nice open on SVACF . Looks like it could Driv818 11/11/15 9:40 AM
Thanks and noted Quokkie 11/10/15 3:39 AM
This is just a dumb comment by you. thought013 11/09/15 7:55 PM
I've been doing this over 15 years with serious38 11/07/15 7:12 AM
Thanks for the information. I am just planning game7alcs 11/06/15 7:39 PM
Only a fool frost groupie would buy now Let Quokkie 11/06/15 6:25 PM
There are other factors to consider when buying serious38 11/06/15 2:05 PM
Am I confused or if I bought VBIV game7alcs 11/06/15 12:55 PM
I know after the merger SVACF & VBIV serious38 11/06/15 11:16 AM
I Bought myself another 10,000 shares today. serious38 11/06/15 10:53 AM
Basic math You own stock trading at $2.56 or Quokkie 11/06/15 8:25 AM
Unless you are an insider how would you Quokkie 11/06/15 7:32 AM
Exactly, this is what I was trying to thought013 11/05/15 6:50 PM
This happens with every merger/buyout. Are you guys JoSquared 11/05/15 12:00 PM
Lots of them Quokkie 11/05/15 10:59 AM
What investigation? Link. Or do you mean thought013 11/04/15 6:53 PM
Vbi is under investigation Quokkie 11/04/15 5:50 PM
Thanks Citrati. I'll check it out. My BooDog 10/29/15 3:16 PM
Boo, make sure to read this.... Citrati 10/29/15 2:46 PM
Looks like Frost may have baited the shorts. UHD 10/28/15 12:58 PM
I sure would love to know How low serious38 10/28/15 9:23 AM
Is this stock a short term hold or riotmaker 10/27/15 10:40 PM
lol no worries. SciVac is unlimited. BooDog 10/27/15 11:35 AM
each share of VBI common stock will be BooDog 10/27/15 11:09 AM
SVACF and OPK new license hidden in todays UHD 10/26/15 10:52 PM
Whats everyone's price projection once the merger happens riotmaker 10/26/15 9:47 PM
Frost made another GREAT merger deal. VBIV is jfk 10/26/15 9:56 AM
SVACF announces big news this morning. The company ItipsDaily 10/26/15 9:25 AM
Yeah seems to be a little bit of JordieSands 10/23/15 3:35 PM
Slight wall there UHD 10/23/15 3:26 PM
Likes Subject

02/26/20 3:37 AM
Mako my Day
04/29/16 8:41 AM
04/28/16 11:17 AM
03/17/16 5:32 PM
02/19/16 5:41 PM
Mako my Day
02/18/16 8:29 AM
12/10/15 4:29 PM
12/07/15 10:42 AM
12/02/15 1:34 PM
11/12/15 1:49 AM
11/11/15 4:08 PM
11/11/15 9:40 AM
11/10/15 3:39 AM
11/09/15 7:55 PM
11/07/15 7:12 AM
11/06/15 12:55 PM
11/06/15 11:16 AM
11/06/15 10:53 AM
11/06/15 7:32 AM
11/05/15 6:50 PM
11/05/15 10:59 AM
11/04/15 6:53 PM
11/04/15 5:50 PM
10/29/15 3:16 PM
10/28/15 9:23 AM
10/27/15 10:40 PM
10/27/15 11:35 AM
10/27/15 11:09 AM
10/23/15 3:35 PM
10/23/15 3:26 PM

SciVac Therapeutics Inc. (SVACD)

Posts (Today)
Posts (Total)


Opko's Frost Inks Levon Deal with Israel's SciVac, a Hint for the Next Merger?

March 20, 2015 11:35 AM


NEW YORK, NY / ACCESSWIRE / March 20, 2015 / On September 11 last year, a little-known Israeli financial magazine called Globes came out with a report that Dr. Phillip Frost, Chairman and CEO of Opko Health (NYSE:OPK), and then Chairman of Teva Pharmaceuticals (NYSE:TEVA), was interested in moving a private Israeli biotech called SciVac, 45% owned by Opko, into a corporate shell and making it public.

Today, Frost accomplished his goal, as SciVac has been officially acquired by Levon Resources (OTCMKTS:LVNVF), with 68.4% of the new company going to the former private SciVac shareholders and 31.6% going to former Levon shareholders. Since Opko already has a 45% stake in SciVac, that brings its total take in SciVac to 30.8%.

The deal still has to be voted on by current Levon shareholders in April, but is expected to pass.

Opko has had some success taking stakes in biotech companies so far this year. Its recent 8% stake in Cocrystal Pharma (OTCBB:COCP) has jumped 100% since February. Cocrystal is its second largest investment behind private Russian biotech Pharmsynthez.

SciVac's Hepatitis B Vaccine

SciVac is the developer of a third generation hepatitis B vaccine (HBV) called Sci-B-Vac . It is approved in several countries including SciVac's home country of Israel, where it is administered to hundreds of thousands of newborns each year. While first generation HBV vaccines are mostly effective, their effectiveness is still only 90%. In a clinical trial of over 5,000 people, Sci-B-Vac was shown to have an effectiveness of greater than 98% with higher immunogenicity, or immune response in terms of antibodies produced.

The difference between Sci-B-Vac and the current standard-of-care HBV vaccine is that Sci-B-Vac is derived from mammalian cells instead of yeast cells, and carries on it the three main HBV surface antigens instead of just one. It is believed that the 10% of people who do not respond to first generation HBV vaccines are infected with mutant versions of HBV that escape the single antigen vaccine. It is much harder for HBV to mutate all three surface antigens simultaneously to escape Sci-B-Vac.

Despite vaccines available, HBV is still a huge pandemic. According to the World Health Organization, one third of the world's population is infected with HBV, with up to 400M people suffering chronic infections leading to chronic liver disease. 250M of those people are in the Asia-Pacific region alone.

SciVac's next regulatory goal is approval in the United States, where 12M people are infected every year despite the current first generation vaccine available. What regulatory hurdles have to be overcome remains to be seen, given that Sci-B-Vac is already clinically tested and approved in several countries. SciVac will be aiming at the immunocompromised as well as end stage renal disease and HIV patients, as these are patient populations who have special difficulties responding to current HBV vaccines.

Context of Frost's Latest Move Hints at Possible Future Moves

Dr. Frost's latest move comes in the context of several other interesting stock movements that may tip off future deals in the making. In October last year, only one month after Globes reported Frost's interest in taking SciVac public, Levon acquired 35M shares, or 10% of Pershing Gold Corporation, another one of Frost's pet projects of which he has a 15% stake translating to 53.7M shares. Those 35M shares of PGLC will be moving to new entity Spinco, so speculators looking out for the next Frost-related deal should keep an eye on a possible merger between Spinco and Pershing. A similar deal was inked bewteen Pershing and Continental Resources Group in February 2013 where the latter was acquired by Pershing. Continental had a substantial stake in Pershing at the time.

Cocrystal, which is fairly similar to SciVac in that it is focusing on molecularly tailored vaccines, primarily hepatitis C. Cocrystal is also 22% owned by Frost through his investment trust as well as an 8% stake through Opko. Cocrystal has skyrocketed over 100% since February but lacking any obvious catalyst for doing so. Another possible move to watch then is for a deal between Levon, now SciVac, and Cocrystal, which itself was once BioZone, also an Opko investment that was merged into Cocrystal.

With Frost's myriad of moves and deals over the last few years things can get admittedly confusing and make your head spin. The structure of these mergers, however, repeatedly seems to start with Opko at the base and then moves out from there. Opko itself has been on a nearly 100% tear since December. As for Cocrystal's recent 100% move, it may have investors scratching their heads but connecting the dots here could point to the beginning stages of a Frost deal at some point between Cocrystal and SciVac as both specialize in hepatitis vaccines, as well as one between Spinco and Pershing.

Call it equity consolidation with synergies in mind, it certainly is a fascinating chess game.


Jun 03, 2015

Levon Shareholders and Optionholders Vote in Favour of the Plan of Arrangement Involving Scivac Ltd. and 1027949 B.C. Ltd.

Levon Resources Ltd. ("Levon" or the "Company") is pleased to announce that Levon's shareholders (the "Shareholders") and optionholders (together with the Shareholders, the "Securityholders") have voted today at the special meeting of Securityholders (the "Meeting") to approve the previously announced plan of arrangement (the "Arrangement") involving SciVac Ltd. ("SciVac"), Levon and 1027949 B.C. Ltd. The Arrangement was approved by 97.64% of the votes cast by Shareholders and 98.06% of the votes cast by Securityholders, voting together as a single class, at the Meeting.

Ron Tremblay, President and Chief Executive Officer of Levon, said "We are pleased that Levon's Securityholders have overwhelmingly approved the Arrangement, helping to create tremendous shareholder value. In a difficult market for resource issuers, Levon has given Shareholders the opportunity to diversify their holdings by spinning out its mining assets and allowing Shareholders to also participate in the pharmaceutical industry through this transaction with SciVac".

For details of the Arrangement, please see Levon's management information circular dated May 1, 2015 and Levon's press release dated March 20, 2015, both of which have been filed on Levon's profile on SEDAR at

Levon's application to the Supreme Court of British Columbia to obtain the final order approving the Arrangement is scheduled for Thursday, June 4, 2015. The Company looks forward to satisfying the remaining conditions and successfully completing the Arrangement.

Shareholders with questions regarding the deposit of Levon shares to the Arrangement can contact Valiant Trust Company at 1-866-313-1872 or by email at

About Levon Resources Ltd.

Levon is a gold and precious metals exploration Company, exploring the Company's 100% owned flagship Cordero bulk tonnage silver, gold, zinc, and lead project near Hidalgo Del Parral, Chihuahua, Mexico.

For further information, contact Levon's Investor Relations directly at 604-682-2991 or the main office number at 778-379-0040.

"Ron Tremblay"
Ron Tremblay
President and Chief Executive Officer
Most Liked Posts
(Last 30 Days)
SVACD Latest News
  • No Recent News Available for this company!
Most Liked Posts
(Last 30 Days)
New Post